Shares of Mirum Pharmaceuticals, Inc. (MIRM) surged 5.05% in pre-market trading on Monday, following a bullish analyst report from Stifel. The biopharmaceutical company, which focuses on developing and commercializing novel therapies for rare liver diseases, saw its stock climb on the back of renewed positive coverage from Wall Street.

Stifel, a prominent investment bank, resumed coverage of Mirum Pharmaceuticals with a "Buy" rating and set an ambitious price target of $89. This target suggests significant upside potential from the stock's previous closing price. James Condulis, an analyst at Stifel Nicolaus, initiated the new Buy rating, citing strong growth prospects for the company in the rare disease market.

The positive analyst sentiment appears to be driving investor enthusiasm for Mirum Pharmaceuticals. As a company focused on addressing unmet needs in liver diseases, this vote of confidence from Stifel could signal growing optimism about the company's pipeline and market potential. Investors will likely be watching closely for any further developments or announcements from Mirum that could support this bullish outlook.